Form 4: Relay Therapeutics CEO Sanjiv Patel Increases Stake Through Employee Stock Purchase Plan

Relay Therapeutics, Inc. President and CEO, Sanjiv Patel, acquired 5,000 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price.

Summary

• Sanjiv Patel, President and CEO, and a Director of Relay Therapeutics, Inc. (RLAY), acquired 5,000 shares of common stock.
• The transaction occurred on June 30, 2025, under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan (ESPP).
• The shares were purchased at a price of $2.94 per share, which represents 85% of the closing price of the Issuer's common stock on June 30, 2025.
• This acquisition is exempt under SEC Rules 16b-3(d) and 16b-3(c).
• Following this transaction, Sanjiv Patel directly beneficially owns 826,667 shares of common stock, which includes 410,560 shares underlying Restricted Stock Units (RSUs).
• Additionally, 199,548 shares are indirectly held by The Patel Family Irrevocable Trust of 2019, and 687,355 shares are indirectly held by The SSP Irrevocable Trust of 2020, for which the reporting person disclaims beneficial ownership.

Sentiment

Score: 7

Explanation: The acquisition of shares by the President and CEO through an employee stock purchase plan is generally viewed positively as it indicates management's confidence and alignment with shareholder interests, though the transaction size is relatively small compared to total holdings.

Positives

• The President and CEO's acquisition of shares through the ESPP indicates confidence in the company's future prospects.
• Participation in an employee stock purchase plan aligns management's interests with those of shareholders.

Future Outlook

This Form 4 filing reports a past transaction and does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reporting person is voluntarily reporting this transaction, which was acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan (ESPP) and exempt under Rule 16b-3(d) and Rule 16b-3(c).
• The reporting person disclaims beneficial ownership of securities held in irrevocable trusts for the benefit of family members, where an independent trustee serves as trustee.

Industry Context

Insider transactions, such as those reported on Form 4, are common disclosures in the public markets. An executive's decision to purchase company stock, even through an employee plan, is often interpreted as a sign of confidence in the company's valuation and future prospects within its industry.

Related Party Transactions

• Shares are indirectly held by The Patel Family Irrevocable Trust of 2019 and The SSP Irrevocable Trust of 2020, which are trusts for the benefit of the reporting person's family members. The reporting person disclaims beneficial ownership of these shares.

Stakeholder Impact

• Shareholders may view the CEO's purchase of additional shares as a positive signal, potentially increasing investor confidence in the company's leadership and future performance.

Key Dates

Keywords

Relay Therapeutics, RLAY, Sanjiv Patel, Form 4, insider transaction, stock purchase, ESPP, beneficial ownership, CEO, Director